Skip to main content
. 2018 Sep 19;19(9):2839. doi: 10.3390/ijms19092839

Figure 4.

Figure 4

Effects of ASEP-P on (A) T-lymphocyte proliferation, (B) B-lymphocyte proliferation, (C) natural killer (NK) cell activity, and (D) white blood cell (WBC) counts in cyclophosphamide (Cy)-induced immunosuppressed mice. The mice were pre-treated with Cy (100 mg/kg for 3 days) for immunosuppression and then orally administered ASEP-P (100 or 200 mg/kg for 14 days). CVT-E002™ (100 mg/kg) was used as a PC. The data are expressed as the means ± standard deviation (n = 10); ## p < 0.01, compared with the vehicle-treated control group; * p < 0.05 and ** p < 0.01 compared with the Cy-treated model group.